Study population
HCPs approached their patients (who visited them for an appointment within the study period) for participation in this study in five academic and seven large non-academic hospitals, spread over the Netherlands. In addition, participants were recruited through the website of the Dutch patient advocate association, called Hematon, and via the CMyLife website [Patient preference was leading in determining group enrolment. Patients who agreed to actively use CMyLife for at least 6 months were enrolled in the treatment group; patients who did not were enrolled in the questionnaire group. Active use in the intervention group comprised receival of adequate support from the CMyLife-team. The support consisted of an instruction package and a kick-off workshop to inform patients about how, when, and why they could and should use CMyLife. The CMyLife-team was reachable for questions during the day and offered all users to help them install the platform. Also, the CMyLife-team gathered feedback from users about if their support was adequate. Patients in the questionnaire group were aware of the existence of CMyLife and the website remained accessible for them. However, they received no support. After enrolment participants received a written baseline questionnaire by mail. Upon completion of the baseline questionnaire, participants actively used (intervention group) or did not actively use (questionnaire group) CMyLife for at least 6 months, after which they completed the post-intervention questionnaire.